NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

行為康復市場-增長、趨勢、COVID-19 影響和預測(2021-2026)

Behavioral Rehabilitation Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

出版商 Mordor Intelligence Pvt Ltd 商品編碼 1008399
出版日期 內容資訊 英文 116 Pages
商品交期: 2-3個工作天內
價格
行為康復市場-增長、趨勢、COVID-19 影響和預測(2021-2026) Behavioral Rehabilitation Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
出版日期: 2021年05月13日內容資訊: 英文 116 Pages
簡介

在 2021 年至 2026 年的預測期內,行為康復市場預計將以 3.5% 的複合年增長率穩定增長。

COVID-19 大流行預計將對市場產生輕微的負面影響。目前,世界各國都面臨著 COVID-19 的嚴重威脅。許多製藥和生物技術公司將研發工作重點放在消毒劑和疫苗的製造上,以滿足客戶不斷增長的需求。由於這種情況,大多數製藥和生物技術公司都將其研發部門集中在識別治療這種疾病的新分子或先導物上。

許多國家/地區已經批准了 COVID-19 疫苗。例如,2020 年 12 月,世界衛生組織 (WHO) 宣佈在全球範圍內驗證輝瑞/BioNTech 的 COVID-19 mRNA 疫苗以供緊急使用。根據 Katya Numbers 等人於 2021 年 1 月發表在 Nature Reviews Neurology 上的一項研究,癡呆症等精神障礙患者存在認知症狀,難以遵守保護程序和生活環境。 COVID-19 感染的風險。在長期護理機構中,它促進了病毒的傳播。此外,患有癡呆症的老年人比沒有癡呆症的老年人更容易出現嚴重的疾病後果。根據路易體協會的說法,患有癡呆症和相關疾病的人應該洗手、保持推薦的物理距離、監測 COVID-19 的症狀、待在家裡等,以防止病毒傳播。它指出很難遵循政府制定的指導方針。由於短期記憶喪失和認知障礙,患有更嚴重癡呆症的人可能無法理解或記住指南。根據 2020 年國家統計局的數據,據報導,癡呆症和阿爾茨海默病是英國與 COVID-19 相關的最常見的既往死亡。

此外,COVID-19 大流行可能會給許多家庭帶來沉重的經濟負擔,並進一步增加他們放棄治療方案的傾向。此外,流行病也會對新產品的發佈產生負面影響,據估計,這是市場增長的最突出因素。例如,2020年4月,由於數據分析的複雜性以及COVID-19對研發資源的影響,百健(Biogen)宣佈推遲向FDA提交阿爾茨海默病和癡呆症藥物。

本報告調查了行為康復市場,並按行為障礙類型、醫療設施、治療、地區和進入市場的公司概況提供了市場概況以及趨勢。

目錄

第 1 章介紹

第 2 章調查方法

第 3 章執行摘要

第 4 章市場動態

  • 市場概覽
  • 市場驅動力
    • 行為康復的發病率和可用性增加
    • 在線諮詢的出現
    • 致力於部分住院計劃 (PHP)
    • 興起的政府倡議
  • 市場限制
    • 缺乏對行為障礙的認識
    • 缺乏適當的救贖
    • 污名對行為障礙人士的影響
  • 波特五力分析

第 5 章市場細分

  • 按行為障礙類型
    • 焦慮症
    • 情緒障礙
    • 藥物濫用障礙
    • 人格障礙
    • 注意力缺陷障礙
  • 醫療機構
    • 門診患者行為康復
    • 住院病人的行為康復
    • 住房行為康復
  • 按處理方法
    • 諮詢
    • 藥物
    • 支持服務
    • 其他
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東和非洲
    • 南美洲

第 6 章競爭形勢

  • 公司簡介
    • Acadia Healthcare
    • AAC HOLDINGS INC.
    • Aurora Behavioral Health System
    • Behavioral Health Group
    • Haven Behavioral Healthcare Inc.
    • Magellan Health Inc.
    • Niznik Behavioral Health
    • Promises Behavioral Health
    • Springstone Inc.
    • Universal Health Services Inc.
    • CRC Health
    • American Addiction Centers, Inc.

第 7 章市場機會和趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 57015

The Behavioral Rehabilitation Market is estimated to grow with a steady CAGR of 3.5 % during the forecast period from 2021-2026.

The COVID-19 pandemic is expected to have a slightly negative impact on the market. At present, countries across the globe are facing a considerable threat of COVID-19 (coronavirus). Many pharmaceutical and biotechnological companies are focusing their R&D activities on manufacturing antiseptic products and vaccines to meet the increased demand from customers. Owing to the situation, most pharmaceutical and biotechnological companies have been focusing their R&D departments on identifying new molecules or leads for the treatment of this disease.​ Many countries have already approved a vaccine for COVID-19. For instance, in December 2020, the World Health Organization (WHO) issued the emergency use validation of Pfizer/BioNTech COVID-19 mRNA vaccine globally. According to a research study by Katya Numbers et al., published in Nature Reviews Neurology in January 2021, stated that people with mental disorders like dementia are at high risk of COVID-19 infection because cognitive symptoms cause difficulty with following safeguarding procedures and living arrangements in care homes facilitate viral spread. Furthermore, older population with dementia are also more likely to have more severe disease consequences than those without dementia. As per Lewy Body Society, stated that people with dementia and related disorders find harder to follow government guidelines designed to prevent the spread of the virus such as washing hands, maintaining the recommended physical distance, monitoring COVID-19 symptoms and staying at home. People with more severe dementia may not be able to understand or remember the guidelines due to their short-term memory loss and cognitive impairment. As per Office for National Statistics UK 2020, stated that dementia and Alzheimer's disease were the most common pre-existing conditions found among deaths involving COVID-19 in United Kingdom.

Furthermore, due to the COVID-19 pandemic, lots of families are facing a significant economic burden, which can lead to an even greater inclination toward letting go of treatment options. Moreover, the pandemic can also have a negative impact on the new product launches, which are estimated to be the most prominent factor of the growth of the market. For instance, in April 2020, Biogen announced that it had delayed Alzheimer's and dementia drug filing to FDA while citing the complexity of data analysis and impact on COVID-19 on its R&D resources

According to the statistics provided by the Mental Health Foundation in 2018, mental health problems were one of the primary causes of rising medical concerns. Furthermore, mental and behavioral health problems are considered to be the primary cause of disability in the age group of 20-29 years, since the past few decades. According to the same source, every year, a large number of people were diagnosed with mental illnesses in the United States. According to the United States Department of Health and Human Services (DHHS) in 2018, one in every five (20%) children and adolescents suffer from mental health disorder at some point in their life. At least, 1 in 10, or about 6 million people suffered serious emotional disturbance at some point in their life.

The treatments for behavioural disorders mainly focuses on behavioural treatment and medication. Parent management training and family therapy are considered quite effective for managing behavioural disorders. Additionally, cognitive behavioral therapy treatment is the most commonly used mechanism for managing the symptoms of behavioral disorders. However, medication treatment for these disorders is targeted toward treating underlying or co-occurring disorders, such as attention deficit hyperactivity disorder (ADHD), depression or anxiety. These developments re expected to positively affect market development.

Key Market Trends

Anxiety Disorder is Expected to Significant Share of the Global Behavioral Rehabilitation Market Over the Forecast Period

The anxiety disorders are different from normal feelings of anxiousness and involve excessive anxiety or fear. According to Our World in Data (OWID), an estimated 284 million people experienced an anxiety disorder in 2017, globally, making it the most prevalent mental health or neurodevelopmental disorder. Whereas, the Anxiety and Depression Association of America (ADAA) states that anxiety disorders are the most common mental illness in the United States, affecting 40 million adults of age 18 and older, i.e., 18.1% of the population each year. Even though anxiety disorders are very much treatable, only 36.9% of those suffering receive treatment, according to the Anxiety and Depression Association of America. Individuals with an anxiety disorder are three to five times more likely to visit the doctor and six times more likely to be hospitalized for psychiatric conditions than those who do not have anxiety disorders. The roots of anxiety disorders are presently unknown but probably involve a combination of factors, including genetic, psychological, environmental, and developmental.

However, many antidepressants, including escitalopram (Lexapro) and fluoxetine (Prozac), can alleviate anxiety disorders and help people lead a normal and productive life. Furthermore, increase in research and development on treatment of anxiety disorders due to overall increasing prevalence of this disorder is expected to drive the market growth over the forecast period.

North America is Expected to Hold the Major Share of the Market Over the Forecast Period

North America is the largest behavioral rehabilitation market in the world, with the United States occupying the major share. The developed countries, including the United States and Canada, have been witnessing a large number of mental health rehabilitation centers opening for the past decade. According to the NIH, in the United States, the prevalence of personality disorder was 9.1%. As per the National Institute of Mental Health, 2018, in the United States, 21.4% of American adults have experienced mood disorders at some point in their lives. It has also been found that there are various new launches in the behavioral health market in North America. For instance, in September 2019, Hackensack Meridian Health launched the first medically integrated urgent care center with behavioral health in the country, with an aim to improve access, better coordinate care, and innovate treatment for people struggling with mental health issues and addiction. Therefore, in addition, favorable government initiatives and a large number of reimbursement options are two of the other factors fueling growth in this region. The Affordable Care Act categorizes behavioral disorders as essential healthcare, which helps in covering the major part of the treatments. Therefore, all these factors affect the growth of the market.

Competitive Landscape

The market is slightly consolidated with a few major players. Currently, many companies are focusing on the development and introduction of novel products and services into the market which is easily affordable and accessible and entering into strategic collaborations and partnerships to enhance their market positions. Some of the key innovations in the market are: In February 2019, Acadia Healthcare acquired the operations and real estate associated with Whittier Pavilion, a premier behavioral healthcare facility located in Haverhill, Massachusetts, and Mission Treatment operates nine comprehensive treatment centers in California, Nevada, Arizona, and Oklahoma.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Prevalence and Availability of Therapies for Behavioral Rehabilitation
    • 4.2.2 Advent of Online Counselling
    • 4.2.3 Increasing Preferences for Partial Hospitalization Programs (PHP)
    • 4.2.4 Rising Government Initiatives
  • 4.3 Market Restraints
    • 4.3.1 Lack of Awareness Regarding Behavioral Disorders
    • 4.3.2 Lack of Proper Reimbursement
    • 4.3.3 Impact of Stigma on People with Behavioral Disorder
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type of Behavioral Disorder
    • 5.1.1 Anxiety Disorder
    • 5.1.2 Mood Disorder
    • 5.1.3 Substance Abuse Disorder
    • 5.1.4 Personality Disorder
    • 5.1.5 Attention Deficit Disorder
  • 5.2 By Healthcare Setting
    • 5.2.1 Outpatient Behavioral Rehabilitation
    • 5.2.2 Inpatient Behavioral Rehabilitation
    • 5.2.3 Residential Behavioral Rehabilitation
  • 5.3 By Treatment Method
    • 5.3.1 Counselling
    • 5.3.2 Medication
    • 5.3.3 Support Services
    • 5.3.4 Other Treatment Methods
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Acadia Healthcare
    • 6.1.2 AAC HOLDINGS INC.
    • 6.1.3 Aurora Behavioral Health System
    • 6.1.4 Behavioral Health Group
    • 6.1.5 Haven Behavioral Healthcare Inc.
    • 6.1.6 Magellan Health Inc.
    • 6.1.7 Niznik Behavioral Health
    • 6.1.8 Promises Behavioral Health
    • 6.1.9 Springstone Inc.
    • 6.1.10 Universal Health Services Inc.
    • 6.1.11 CRC Health
    • 6.1.12 American Addiction Centers, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS